The insulin receptor (IR ... Whether the two phosphorylated tyrosine kinase domains within the receptor dimer function independently or cooperatively to phosphorylate protein substrates is ...

and insulin receptor (InsR). However, it is unknown whether and how mTOR regulates IGF-IR and InsR themselves. Here we show that mTOR possesses unexpected tyrosine kinase activity and activates ...

"Insulin binding to InsRα derepresses the tyrosine kinase activity of the β-subunit (InsRβ). This initiates a whole metabolic pathway with different steps that eventually allow glucose ...

Activated PKCε binds to and inhibits the insulin receptor tyrosine kinase, leading to decreased insulin-stimulated glycogen synthesis in the liver owing to decreased phosphorylation of GSK3.

The insulin and the IGF-1 pathway are closely ... and BsAb) and small-molecule tyrosine kinase inhibitors are being evaluated for their ability to block signaling and, hence, the survival and ...

Phase I, dose-finding study of monotherapy with AZD8931, an inhibitor of ErbB1, 2, and 3 signaling, in patients (pts) with advanced solid tumors. This is an ASCO Meeting Abstract from the 2011 ASCO ...

Some examples include the epidermal growth factor receptor, platelet-derived growth factor receptor, and insulin receptor. Activation of intracellular tyrosine kinase by these growth factors ...

Tyrosine kinase inhibitors, such as gefitinib (Iressa ™, ZD1839), block the EGFR. As a result, there is inhibition of cellular proliferation, promotion of apoptosis, and inhibition of anti ...

type 2 diabetes or cardiovascular disease, among others. Recent findings have suggested that EphB tyrosine kinase receptor and its ligand, ephrin B, may be involved in insulin signaling.

Background: OSI-906 is a potent inhibitor of IGF-1R and IR tyrosine kinase activity. Increased IGF-1R activity is observed in human malignancies and implicated in resistance to chemotherapy. Methods: ...